Comparison of Point-of-care Produced CAR T-cell with Commercial CAR T-cells in Patients with R/R LBCL

This study is comparing two types of CAR T-cell therapy for people with relapsed or treatment-resistant large B-cell lymphoma: a commercial CAR T product versus one made on-site at the point of care. Both are engineered immune cell therapies designed to attack lymphoma cells. **You may be eligible if...** - You have been diagnosed with diffuse large B-cell lymphoma (DLBCL) or a related subtype - Your lymphoma has come back or stopped responding to at least 2 previous treatments - You are 18 or older and in acceptable health (ECOG 0–2) - Your life expectancy is more than 3 months beyond your lymphoma - You are willing to use contraception if of childbearing potential **You may NOT be eligible if...** - You have untreated central nervous system involvement causing symptoms - Your organ function is too poor to tolerate the therapy - You have an active serious infection - You do not meet the performance status requirements Talk to your doctor to see if this trial is right for you.